SinoFresh Healthcare for sinus problems
 Sinofresh healthcare moisturizing nasal spray keeps you fresh throughout the day

Company
Background
Management Team
Press Releases
Medical Papers
 

Investor Relations
SEC Filings
Shareholder Info
 

Sinofresh provides a complete medical care for chronic sinus

Medical Paper Papers

1: Cochrane Database Syst Rev. 2003;(2):CD000243.

Antibiotics for acute maxillary sinusitis.


Update of: Cochrane Database Syst Rev. 2000;(2):CD000243.


Williams JW Jr, Aguilar C, Cornell J, Chiquette ED, Makela M, Holleman DR, Simel DL.
Medicine, Durham Veterans Affairs Medical Center/ Duke University Medical
Center, 508 Fulton Street, HSRD (152), Durham, NC 27705, USA.
willi007@mc.duke.edu


BACKGROUND: For adults seeking care in ambulatory medical practices, sinusitis is the most common diagnosis treated with antibiotics. OBJECTIVES: We examined whether antibiotics are indicated for acute sinusitis, and if so, which antibiotic classes are most effective. SEARCH StrATEGY: Relevant studies were identified from searches of MEDLINE and EMBASE in December 2001, contacts with pharmaceutical companies and bibliographies of included studies. SELECTION

CRITERIA: Randomized trials were eligible that compared antibiotic to control or antibiotics from different classes, for acute maxillary sinusitis. Additional criteria for inclusion were diagnostic confirmation by radiograph or sinus aspiration, outcomes that included clinical cure or improvement, and a sample size of 30 or more adults. Of 2058 potentially relevant studies, two or more reviewers identified 49 studies meeting selection criteria.

DATA COLLECTION AND ANALYSIS: Data were extracted independently by two persons and synthesized descriptively. Some data were analyzed quantitatively using a random effects model. Primary outcomes were: a) clinical cure, and b) clinical cure or improvement. Secondary outcomes were radiographic improvement, relapse rates, and dropouts due to adverse effects. MAIN RESULTS: Forty-nine trials, involving 13,660 participants, evaluated antibiotic treatment for acute maxillary sinusitis. Major comparisons were antibiotic versus control (n of 5); newer, non-penicillin antibiotic versus penicillin class (n of 10); and amoxicillin-clavulanate versus other extended spectrum antibiotics (n of 17), where n is the number of trials. Most trials were conducted in otolaryngology settings. Only 8 trials described adequate allocation and concealment procedures; 20 were double-blind. Compared to control, penicillin improved clinical cures [relative risk (RR) 1.72; 95% CI 1.00 to 2.96]. Treatment with amoxicillin did not significantly improve cure rates (RR 2.06; 95% CI 0.65 to 6.53) but there was significant variability between studies. Radiographic outcomes were improved by antibiotic treatment. Comparisons between classes of antibiotics showed no significant differences: newer non-penicillins versus penicillins (RR for cure 1.07; 95% CI 0.99 to 1.17); newer non-penicillins versus amoxicillin-clavulanate (RR for cure 1.03; 95% CI 0.96 to 1.11). Compared to amoxicillin-clavulanate, dropouts due to adverse effects were significantly lower for cephalosporin antibiotics (RR 0.47; 95% CI 0.30 to 0.73). Relapse rates within one month of successful therapy were 7.7%. REVIEWER`S

CONCLUSIONS: For acute maxillary sinusitis confirmed radiographically or by aspiration, current evidence is limited but supports the use of penicillin or amoxicillin for 7 to 14 days. Clinicians should weigh the moderate benefits of antibiotic treatment against the potential for adverse effects.

Publication Types:
  • Review
  • Review Academic

PMID: 12804392 [PubMed - indexed for MEDLINE]


 
©2009 SinoFresh HealthCare, Inc. All rights reserved.

This site is governed solely by applicable U.S. laws and governmental regulations. Please see our Privacy Policy and our Terms of Use. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy and to our Terms of Use Agreement. Your use of the information on this site is subject to our Terms of Use Agreement and the legal notices contained therein. You should review the Press Release section and the most recent SEC filings in the Investor Relations section in order to receive the most current information made available by SinoFresh HealthCare, Inc.